BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7150794)

  • 1. [Problems raised by interim analysis in therapeutic trials].
    Rodary C; Nougue CC
    Bull Cancer; 1982; 69(4):387-92. PubMed ID: 7150794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analyses for randomized clinical trials: the group sequential approach.
    Pocock SJ
    Biometrics; 1982 Mar; 38(1):153-62. PubMed ID: 7082757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
    BĂ©nichou J; Lepage E; Chastang C
    Nouv Rev Fr Hematol (1978); 1987; 29(1):87-91. PubMed ID: 3473443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sequential analysis in clinical and epidemiological research].
    van der Tweel I; Schipper M
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2348-52. PubMed ID: 12510397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.
    Geller NL; Pocock SJ
    Biometrics; 1987 Mar; 43(1):213-23. PubMed ID: 3567306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Group sequential experiments. Short introduction and review].
    Lehmann EH; Sandvik H
    Tidsskr Nor Laegeforen; 1997 Jan; 117(1):47-9. PubMed ID: 9064810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of sequential methods in randomized clinical trials with censored response criteria].
    Benichou J; Chastang C
    Rev Epidemiol Sante Publique; 1986; 34(3):196-208. PubMed ID: 3786877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analyses and early termination of clinical trials.
    Choi SC
    J Biopharm Stat; 1997 Nov; 7(4):533-43. PubMed ID: 9358327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
    Thorlund K; Devereaux PJ; Wetterslev J; Guyatt G; Ioannidis JP; Thabane L; Gluud LL; Als-Nielsen B; Gluud C
    Int J Epidemiol; 2009 Feb; 38(1):276-86. PubMed ID: 18824467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
    Emerson SS
    Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of logrank tests and group sequential methods at fixed calendar times.
    DeMets DL; Gail MH
    Biometrics; 1985 Dec; 41(4):1039-44. PubMed ID: 4096915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.
    Brok J; Thorlund K; Gluud C; Wetterslev J
    J Clin Epidemiol; 2008 Aug; 61(8):763-9. PubMed ID: 18411040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statistical methods in the evaluation of the therapeutic efficacy--their problems and solutions].
    Tominaga S
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1873-81. PubMed ID: 6764094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.